Vebicorvir Bioactivity,Chemical Properties,Storage & Solubility Information Pathways-PeptideDB

Description	Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity.
In vitro	Vebicorvir展现了对HBV DNA复制的选择性抑制（50%有效浓度[EC50]从173 nM到307 nM）。更重要的是，在两种de novo感染模型中，Vebicorvir能够抑制共价闭合圆形DNA（cccDNA）的形成，其EC50值介于1.84 μM至7.3 μM之间。作用机制研究表明，Vebicorvir是一种直接作用的抗病毒化合物，它针对HBV核心蛋白，阻止HBV前基因组RNA（pgRNA）的封装和随后的DNA复制。
Synonyms	ABI-H0731
molecular weight	467.44
Molecular formula	C19H12F3N3O4S2
CAS	2090064-66-5
Storage	\|Powder: -20°C for 3 years \| In solvent: -80°C for 1 year
Solubility	DMSO: 60 mg/ml (128.36 mM)
References	1. Huang Q, Cai D, Yan R, Li L, Zong Y, Guo L, Mercier A, Zhou Y, Tang A, Henne K, Colonno R. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01463-20. 2. Smolders EJ, Burger DM, Feld JJ, Kiser JJ. Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. Aliment Pharmacol Ther. 2020 Jan;51(2):231-243. doi: 10.1111/apt.15581. Epub 2019 Dec 16. 3. Yuen MF, Agarwal K, Gane EJ, Schwabe C, Ahn SH, Kim DJ, Lim YS, Cheng W, Sievert W, Visvanathan K, Ruby E, Liaw S, Yan R, Huang Q, Colonno R, Lopatin U. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166.

PeptideDB

Vebicorvir

CAS No.: 2090064-66-5